Endo, Impax Schemed To Delay Opana Generics, Suit Says

Law360, New York (June 6, 2014, 3:00 PM EDT) -- Endo Pharmaceuticals Inc. and Impax Laboratories Inc. were hit with a proposed antitrust class action in Pennsylvania federal court Wednesday alleging Endo paid Impax more than $112 million to delay generic versions of Endo's patented Opana ER painkiller from hitting the market.

Plaintiff Rochester Drug Cooperative Inc. accused Endo, as well as its subsidiary Penwest Pharmaceuticals Co., of crafting a scheme in which Endo paid Impax more than $112 million in cash in exchange for Impax agreeing to delay the launch of its cheaper, generic version...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.